Sign In
Buy OVID
$2.44
-0.0100 (-0.408%)
At Close: Jul 17, 2026
NEW YORK, March 18, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company developing small molecule medicines for brain disorders with significant unmet need, tod
Ovid Therapeutics Announces Pricing of $60 Million Private Placement
06:00am, Wednesday, 18'th Mar 2026
NEW YORK, March 18, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company developing small molecule medicines for brain disorders with significant unmet need, tod
Ovid Therapeutics to Participate in Upcoming Investor Conferences
07:00am, Wednesday, 25'th Feb 2026
NEW YORK, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company developing small molecule medicines to treat brain disorders and symptoms caused by exces
Ovid Therapeutics: Bullish Post-PIPE With 2 Differentiated CNS Moonshots
11:01pm, Monday, 26'th Jan 2026
Ovid Therapeutics targets neuronal hyperexcitability with two small-molecule platforms. 1) OV329 (GABA-AT inhibition) and 2) KCC2 direct activators for neuropsychiatric disorders. OV329 Phase 2a in dr
Ovid Therapeutics (NASDAQ:OVID) Receives Consensus Recommendation of “Buy” from Analysts
02:04am, Saturday, 10'th Jan 2026
Shares of Ovid Therapeutics (NASDAQ: OVID - Get Free Report) have been given a consensus rating of "Buy" by the eleven research firms that are presently covering the company, Marketbeat.com reports. O
Assenagon Asset Management S.A. Purchases 488,956 Shares of Ovid Therapeutics $OVID
03:21am, Thursday, 25'th Dec 2025
Assenagon Asset Management S.A. lifted its position in shares of Ovid Therapeutics (NASDAQ: OVID) by 112.2% during the third quarter, according to its most recent filing with the Securities and Exchan
OV350 showed a good safety profile, supporting the advancement of the Company's KCC2 portfolio, including the first oral direct activator, OV4071 There were no treatment-related laboratory findings, n
Ovid Therapeutics Appoints Dr. Petra Kaufmann as Chief Medical Officer
07:00am, Tuesday, 02'nd Dec 2025
NEW YORK, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company developing small molecule medicines for brain disorders with significant unmet need, toda
Ovid Therapeutics (OVID) Reports Q3 Loss, Lags Revenue Estimates
09:11am, Wednesday, 12'th Nov 2025
Ovid Therapeutics (OVID) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to a loss of $0.2 per share a year ago.
Ovid Therapeutics Announces Planned Leadership Succession and Reports Business Updates and Third Quarter 2025 Financial Results
07:00am, Wednesday, 12'th Nov 2025
Meg Alexander appointed Chief Executive Officer effective January 1, 2026; Dr. Jeremy M. Levin to transition to Executive Chair of the Board of Directors Next-generation GABA-aminotransferase (GABA-AT
Ovid Therapeutics (OVID) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
11:01am, Tuesday, 04'th Nov 2025
Ovid Therapeutics (OVID) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
OVID Stock Soars 39% in a Month Following Upbeat Epilepsy Study Data
11:31am, Friday, 10'th Oct 2025
Ovid Therapeutics jumps 39% in a month after phase I epilepsy study data show superior efficacy of its lead candidate, OV329, hinting at best-in-class potential.
Ovid Therapeutics (OVID) Is Up 42.98% in One Week: What You Should Know
01:01pm, Monday, 06'th Oct 2025
Does Ovid Therapeutics (OVID) have what it takes to be a top stock pick for momentum investors? Let's find out.
Ovid Therapeutics Inc. - Special Call
12:52pm, Friday, 03'rd Oct 2025
Ovid Therapeutics Inc. - Special Call Company Participants Victoria Fort - Senior Vice President of Corporate Affairs & Corporate Strategy Jeremy Levin - CEO & Chairman Meg Alexander - President & COO
Ovid Therapeutics Announces Pricing of Private Placement Totaling up to $175 Million in Gross Proceeds
07:05am, Friday, 03'rd Oct 2025
Initial closing of approximately $81 million expected to fund current operating plan and clinical pipeline into 2028, with potential for up to $94 million in additional proceeds upon exercise of issue
